10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
In this episode of Trekking Through Compliance, we consider the episode Day of the Dove which aired ...
Read More >
Divestment activity is poised to increase over previous years as COVID-19 economic conditions put pr...
Read More >
By now, you most likely have heard the phrase “OK Boomer.” What began as a meme, quickly went vir...
Read More >
In In re USG Corp. S’holder Litig., 2020 WL 5126671 (Del. Ch. Aug. 31, 2020), the Court of Chancery...
Read More >
A great deal has been written about the M&A wars, including our prior alerts regarding the issues th...
Read More >
The non-ERISA §403(b) space is the last bastion of high, hidden costs in retirement plans. That’s t...
Read More >